Aerie Pharmaceuticals is a company that focuses on the development and commercialization of therapies for the treatment of glaucoma and other eye diseases. The National Eye Institute expects the number of people in the United States suffering from glaucoma to reach 4.3 million by 2030. Aerie was founded in 2005 and went in public in 2013, raising $67 million in its IPO. Its product candidates include Rhopressa and Roclatan. The company is headquartered in Irvine, California.